<DOC>
	<DOCNO>NCT00102024</DOCNO>
	<brief_summary>This Phase I/II open-label , dose-escalating study patient metastatic colorectal cancer . The objective study obtain information safety radiolabeled IDEC-159 , well activity colorectal cancer . Another objective determine maximum tolerate dose ( MTD ) . The study duration 2 year visit occur daily and/or weekly first 3 month , every 6 week end 2 year period .</brief_summary>
	<brief_title>Safety Activity 90Y-Labeled IDEC-159 Subjects With Metastatic Colorectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Sign Institutional Review Board ( IRB ) approve informed consent . Metastatic colorectal adenocarcinoma pathologically confirm follow fail response relapse follow fluoropyrimidine , irinotecan , oxaliplatin chemotherapy . ( Prior therapy cetuximab recommend tumor epidermal growth factor receptor [ EGFR ] positive . ) Age 18 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . Recovered baseline toxicity significant toxicity associate prior surgery , chemotherapy , biological therapy , investigational drug . Adequate bone marrow reserve ( absolute neutrophil count &gt; 1500 cells/mm3 , platelet count &gt; 125,000 cells/mm3 , hemoglobin concentration â‰¥ 10 g/dL ) . Radiographically measurable disease ( RECIST criterion ) . Life expectancy least 3 month . Male female subject reproductive potential must agree follow accepted birth control method , determine investigator , treatment 12 month completion treatment . Prior radioimmunotherapy . Known presence central nervous system ( CNS ) metastasis . Any lesion &gt; 7.5 cm . Total bilirubin &gt; 2.0 mg/dL . Total creatinine &gt; 2.0 mg/dL . AST ALT &gt; 2.5 time upper limit normal ( ULN ) , metastases liver &gt; 5 time ULN . Presence second primary malignancy require active treatment ( except hormonal therapy ) . Serious nonmalignant disease infection , opinion either investigator sponsor , would compromise protocol objective . History external beam radiation therapy &gt; 25 % active bone marrow . History bone marrow stem cell transplant . History granulocyte colonystimulating factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) therapy within 2 week Study Day 1 . History pegylated GCSF therapy within 4 week Study Day 1 . History major surgery , diagnostic surgery , within 4 week Study Day 1 . History receive investigational product within 4 week Study Day 1 long term toxicity previous investigational therapy . Known history HIV AIDS . Concurrent systemic corticosteroid therapy immunosuppressive agent , unless treatment compute tomography ( CT ) dye allergy reaction . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Metastatic Colorectal Adenocarcinoma</keyword>
	<keyword>Anti TAG-72</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>